Pieridae Releases Q1 2024 Financial and Operating Results and Revises 2024 Guidance
May 08, 2024 18:10 ET
|
Pieridae Alberta Production Ltd.
CALGARY, Alberta, May 08, 2024 (GLOBE NEWSWIRE) -- Pieridae Energy Limited (“Pieridae” or the “Company”) (TSX: PEA) announces the release of its first quarter 2024 financial and operating results....
Dianthus Therapeutics to Participate in the Bank of America Securities 2024 Health Care Conference
May 08, 2024 16:30 ET
|
Dianthus Therapeutics, Inc.
NEW YORK and WALTHAM, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of...
Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update
May 08, 2024 16:15 ET
|
Merus N.V.
Petosemtamab in combination with pembrolizumab in 1L HNSCC initial interim clinical data at 2024 ASCO Annual Meeting; preparing for a potential phase 3 trialZeno BLA accepted for priority review by...
Oculis Reports Q1 2024 Financial Results and Provides Company Updates
May 08, 2024 16:10 ET
|
Oculis Holding AG
ZUG, Switzerland, May 08, 2024 (GLOBE NEWSWIRE) -- Clinical programs progressing as planned with initiation of second OCS-01 Phase 3 DIAMOND-2 trial in Diabetic Macular Edema (DME) and completion of...
Oculis Reports Q1 2024 Financial Results and Provides Company Updates
May 08, 2024 16:10 ET
|
Oculis Holding AG
Clinical programs progressing as planned with initiation of second OCS-01 Phase 3 DIAMOND-2 trial in Diabetic Macular Edema (DME) and completion of enrollment in OCS-02 (licaminlimab) Phase 2b RELIEF...
Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update
May 08, 2024 16:10 ET
|
Pharvaris N.V.
RAPIDe-3, a global pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, currently enrollingEnd-of-Phase 2 meeting scheduled to discuss development plan of deucrictibant...
CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager)
May 08, 2024 16:10 ET
|
CytomX Therapeutics Inc.
- CX-904 demonstrated a favorable safety profile with no cytokine release syndrome (CRS) of any grade observed in step-dosing cohorts and no grade >1 CRS observed overall - - Encouraging initial...
CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
May 08, 2024 16:10 ET
|
CytomX Therapeutics Inc.
- Company announces positive initial Phase 1a dose escalation data for monotherapy CX-904 (EGFRxCD3 T-cell engager) in solid tumors - - First dose cohort cleared in Phase 1 clinical study of CX-2051,...
Crinetics Pharmaceuticals to Present Advancements from Atumelnant (CRN04894) and Paltusotine Development Programs at ENDO 2024
May 08, 2024 16:05 ET
|
Crinetics Pharmaceuticals, Inc.
Initial Data from Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia to be Presented, Along with Initial Findings from Phase 1b/2a ACTH-Dependent Cushing’s Syndrome Trial Data from Phase 3...
Amplify Energy Announces First Quarter 2024 Results and Improved 2024 Guidance
May 08, 2024 16:05 ET
|
Amplify Energy Corp.
HOUSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Amplify Energy Corp. (NYSE: AMPY) (“Amplify,” the “Company,” “us,” or “our”) announced today its operating and financial results for the first quarter of...